Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Follicular 3Lymphoma, Mantle-Cell 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Leukemia, Lymphocytic, Chronic, B-Cell 2Waldenstrom Macroglobulinemia 1Recurrence 1Optic Neuritis 1Neuromyelitis Optica 1Myelitis, Transverse 1

Interventions

Rituximab 226Cyclophosphamide 202fludarabine phosphate 108Peripheral Blood Stem Cell Transplantation 103Filgrastim 87Etoposide 76Cytarabine 70ibrutinib 68Mycophenolic Acid 67Bortezomib 66Whole-Body Irradiation 63Cyclosporine 63Melphalan 59Lenalidomide 59Bendamustine Hydrochloride 58Vincristine 53Radiotherapy 53fludarabine 52Tacrolimus 50Doxorubicin 48Busulfan 48Methotrexate 47Antilymphocyte Serum 42Prednisone 41Carmustine 40Dexamethasone 38Granulocyte Colony-Stimulating Factor 33venetoclax 32acalabrutinib 31zanubrutinib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, Mantle-Cell × LFB-R603 × Clear all
NCT04783415 2024-12-02

Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

City of Hope Medical Center

Phase 2 Active not recruiting
12 enrolled 8 charts
Lymphoid

Lymphoma, Mantle-Cell

NCT04635683 2022-09-30

Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1 Withdrawn
Lymphoid

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡